Vahanian & Associates Financial Planning’s CRISPR Therapeutics CRSP Stock Holding History

Vahanian & Associates Financial Planning’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$286K	Buy	+4,575	New	+$253K	1.13%	31

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vahanian & Associates Financial Planning's CRSP Position: Q4 2023 in Review

Vahanian & Associates Financial Planning opened a new position in CRISPR Therapeutics (CRSP) in Q4 2023: 4,575 shares worth $286K. The stake represents 1.13% of the portfolio and ranks #31 among its holdings.

472 funds tracked by Wall St. Rank hold CRSP as of Q4 2023.

Vahanian & Associates Financial Planning held 4,575 shares of CRISPR Therapeutics worth $286K as of Q4 2023.
CRISPR Therapeutics was a new Vahanian & Associates Financial Planning position in Q4 2023.
CRISPR Therapeutics made up 1.13% of Vahanian & Associates Financial Planning's portfolio in Q4 2023, its #31 holding.
472 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2023.

Based on Vahanian & Associates Financial Planning's 13F filing for Q4 2023, filed 25 Jan 2024.